Zentalis Pharmaceuticals (ZNTL) to Release Earnings on Wednesday

Zentalis Pharmaceuticals (NASDAQ:ZNTL) is expected to be posting its Q4 2025 results before the market opens on Wednesday, March 25th. Analysts expect Zentalis Pharmaceuticals to post earnings of ($0.41) per share for the quarter. Individuals are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Friday, March 27, 2026 at 5:00 PM ET.

Zentalis Pharmaceuticals Stock Up 0.7%

Shares of ZNTL stock opened at $2.73 on Wednesday. The company has a market capitalization of $197.24 million, a P/E ratio of -1.32 and a beta of 1.71. Zentalis Pharmaceuticals has a 12-month low of $1.01 and a 12-month high of $3.95. The firm has a 50-day moving average price of $2.68 and a 200 day moving average price of $1.90.

Insider Buying and Selling

In related news, insider Vincent Vultaggio sold 29,951 shares of the stock in a transaction that occurred on Friday, February 6th. The shares were sold at an average price of $2.43, for a total transaction of $72,780.93. Following the sale, the insider owned 156,779 shares in the company, valued at approximately $380,972.97. This trade represents a 16.04% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, major shareholder Group Walters acquired 6,459,973 shares of the firm’s stock in a transaction that occurred on Wednesday, December 31st. The stock was purchased at an average cost of $1.20 per share, for a total transaction of $7,751,967.60. Following the completion of the purchase, the insider directly owned 13,509,973 shares of the company’s stock, valued at $16,211,967.60. The trade was a 91.63% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last ninety days, insiders have sold 46,617 shares of company stock valued at $113,417. 1.90% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Zentalis Pharmaceuticals

Large investors have recently modified their holdings of the company. Millennium Management LLC increased its stake in Zentalis Pharmaceuticals by 220.6% during the 1st quarter. Millennium Management LLC now owns 3,069,514 shares of the company’s stock valued at $4,881,000 after purchasing an additional 2,111,951 shares in the last quarter. Vanguard Group Inc. lifted its stake in shares of Zentalis Pharmaceuticals by 0.7% in the third quarter. Vanguard Group Inc. now owns 2,904,400 shares of the company’s stock valued at $4,386,000 after buying an additional 19,768 shares in the last quarter. Renaissance Technologies LLC grew its holdings in shares of Zentalis Pharmaceuticals by 24.0% during the fourth quarter. Renaissance Technologies LLC now owns 2,883,745 shares of the company’s stock valued at $3,893,000 after buying an additional 558,390 shares during the last quarter. Bank of America Corp DE grew its holdings in shares of Zentalis Pharmaceuticals by 117.1% during the third quarter. Bank of America Corp DE now owns 1,548,781 shares of the company’s stock valued at $2,339,000 after buying an additional 835,466 shares during the last quarter. Finally, Opaleye Management Inc. increased its position in shares of Zentalis Pharmaceuticals by 342.6% during the fourth quarter. Opaleye Management Inc. now owns 1,400,906 shares of the company’s stock worth $1,891,000 after acquiring an additional 1,084,356 shares in the last quarter.

Analyst Ratings Changes

Separately, Wells Fargo & Company began coverage on shares of Zentalis Pharmaceuticals in a report on Tuesday. They set an “equal weight” rating and a $5.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $5.00.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.